Literature DB >> 19519411

A critical review of methods for size characterization of non-particulate protein aggregates.

John S Philo1.   

Abstract

Although size exclusion chromatography (SEC) has been, and will continue to be, the primary analytical tool for characterization of the content and size distribution of non-particulate aggregates in protein pharmaceuticals, regulatory concerns are driving increased use of alternative and complementary methods such as analytical ultracentrifugation and light scattering techniques. This review will highlight and critically review the capabilities, advantages, and drawbacks of SEC, analytical ultracentrifugation, and light scattering methods for characterizing aggregates with sizes below about 0.3 microns. The physical principles of the biophysical methods are briefly described and examples of data for real samples and how that data is interpreted are given to help clarify capabilities and weaknesses.

Mesh:

Substances:

Year:  2009        PMID: 19519411     DOI: 10.2174/138920109788488815

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  35 in total

1.  Preparative scale cell-free production and quality optimization of MraY homologues in different expression modes.

Authors:  Yi Ma; Daniela Münch; Tanja Schneider; Hans-Georg Sahl; Ahmed Bouhss; Umesh Ghoshdastider; Jufang Wang; Volker Dötsch; Xiaoning Wang; Frank Bernhard
Journal:  J Biol Chem       Date:  2011-09-20       Impact factor: 5.157

Review 2.  Biosimilarity Versus Manufacturing Change: Two Distinct Concepts.

Authors:  Paul Declerck; Mourad Farouk-Rezk; Pauline M Rudd
Journal:  Pharm Res       Date:  2015-09-17       Impact factor: 4.200

3.  In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice.

Authors:  Vasco Filipe; Ivo Que; John F Carpenter; Clemens Löwik; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-08-15       Impact factor: 4.200

4.  Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis.

Authors:  R Blake Pepinsky; Laura Silvian; Steven A Berkowitz; Graham Farrington; Alexey Lugovskoy; Lee Walus; John Eldredge; Allan Capili; Sha Mi; Christilyn Graff; Ellen Garber
Journal:  Protein Sci       Date:  2010-05       Impact factor: 6.725

5.  Multi-attribute PAT for UF/DF of Proteins-Monitoring Concentration, particle sizes, and Buffer Exchange.

Authors:  Laura Rolinger; Matthias Rüdt; Juliane Diehm; Jessica Chow-Hubbertz; Martin Heitmann; Stefan Schleper; Jürgen Hubbuch
Journal:  Anal Bioanal Chem       Date:  2020-02-18       Impact factor: 4.142

Review 6.  Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors:  Satish K Singh; Donna L Luisi; Roger H Pak
Journal:  Pharm Res       Date:  2015-05-19       Impact factor: 4.200

Review 7.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

8.  Taylor dispersion analysis compared to dynamic light scattering for the size analysis of therapeutic peptides and proteins and their aggregates.

Authors:  Andrea Hawe; Wendy L Hulse; Wim Jiskoot; Robert T Forbes
Journal:  Pharm Res       Date:  2011-05-11       Impact factor: 4.200

9.  Challenges and opportunities in the advancement of nanomedicines.

Authors:  Alexander Wei; Jonathan G Mehtala; Anil K Patri
Journal:  J Control Release       Date:  2012-10-12       Impact factor: 9.776

Review 10.  Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies.

Authors:  Hao Zhang; Weidong Cui; Michael L Gross
Journal:  FEBS Lett       Date:  2013-11-26       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.